Accelerating the DMTA Cycle: Merck's Automated Data Workflow with Genedata Screener
In this webinar, learn how Merck Healthcare is accelerating drug discovery by building an integrated data ecosystem using the Genedata platform to streamline workflows, reduces cycle times, and enables AI/ML-driven decision-making.
Bolek Zapiec, Director, Head of Digital & Data Science at Merck, will share how their Discovery Pharmacology team implemented a fully automated data workflow using Genedata Screener. This end-to-end solution — from data load through QC and reporting — supports high-throughput screening (HTS) and Hit-to-Lead activities, enabling faster, more informed decisions across the DMTA (Design-Make-Test-Analyze) cycle.
Learn how Merck uses Genedata to:
- Accelerate DMTA cycles by automating data processing and analysis.
- Integrate multi-modal data to support AI/ML-driven candidate prioritization.
- Streamline data flows across Discovery Pharmacology labs.
- Ensure data quality, consistency, and traceability across the pipeline.
- Reduce manual effort and cycle times through end-to-end workflow automation.
Who Should Watch:
- Discovery Scientists & HTS Specialists: Learn how automation accelerates hit identification and validation.
- Data Scientists & AI/ML Teams: See how integrated data ecosystems enable predictive modeling and candidate ranking.
- IT & Digital Transformation Leaders: Explore scalable, automated solutions for data management in drug discovery.
- Research and Development Managers: Understand how workflow automation improves efficiency and decision-making.
- Biopharma Executives: Gain insights into how automation and data integration drive innovation and operational efficiency in early drug discovery.